Category Archives: Individual Stock

Investment Observation: Supervalu (SVU) at $12.81

Supervalu (SVU) has been on our watch list since December 2009. After considerable analysis, I decided to pull the trigger today at $12.81, less than 5% within the 52-week low. My model showed the price of $12 to be the buy range and $15 to be the fair value. The negative earnings on the surface is a concern. However, a deeper investigation shows that the company was forced to take an impairment charge of $3,250 back in January of 2009 because of the Statement of Financial Accounting Standards (SFAS) No. 142 accounting rule. This resulted in a negative earning of $13.95 per share. The quote below was taken from the SEC filing.

For the third quarter of fiscal 2009 the Company’s stock price had a significant and sustained decline and book value per share substantially exceeded the stock price. Consistent with SFAS No. 142, the Company performed an interim impairment test of goodwill and indefinite-lived intangible assets at the end of the third quarter of fiscal 2009. Although this analysis has not been completed due to its complexity, based on the work performed to date the Company has recorded a preliminary estimate of impairment charges of $3,250, comprised of $3,000 of goodwill and $250 of indefinite-lived intangibles.

I recalled that SVU was trading at a 70% discount to book during the March low. After an adjustment, it has a book value of $12.79. I purchased the shares at book value.
Despite the consideration of these adjustments, not all is bright for SVU. The company's operating margin is 3.09%, very low compared to its competitors. A large amount of long-term debt ($8 billion) is a dark cloud that hangs over the company. Large capital expenditure will deplete their cash flow if the economy doesn't pick up. After 35 years of consecutive dividend increases, the company reduced their distribution by 50% and now pays out $0.35 or 2.8% annually. All of these factors contributed to SVU trading at such discounted level.

Forward P/E is at 6.64 times. The price-to-sales ratio is at a low of 0.06. Price-to-book value is at 1. Current dividend yield of 2.8% which exceeds the five year average yield of 2.5%. The current ratio of 1 means that the company can turn over their current assets at the same rate as their current liabilities. This is important for short-term viability concerns.

Fundamental aside, it was the technicals of SVU that prompted me to buy. From the chart below, you can see that for most of 2009 the stock trade within the $17 and $12 range. As business conditions improved and the company returned to profitability in the second half of the year, shares remained unchanged. The stock appears to be "bottoming" as it remains range bound. The moving averages are doing the same as well. A break below $12 would spell trouble and I would get out while a breakout above $17 will signal better times for SVU.
I bought the stock at $12.81 and will sell if it break below $12 (-7%). Profit will be taken around $15 (+17%).
The purpose of our investment observations is to point out quality Dividend Achievers and formers that are near a 52-week low. From this point begins the fundamental research to verify the quality of the stock for both short and long-term investing. These recommendations are within the context of the 3rd year of an 18-year secular bear market. A bear market that we expect could trade in a range between 16,000 and 5,000. The secular bear market will be considered over when the Dow Transports and Dow Industrials exceed their respective peaks on high volume or the dividend yield on the Dow exceeds 6% or higher. -Art

Buffett Buy Low

Some of you may know that I bought Wal-Mart in September. Today news from CNBC was most welcomed as Warren Buffett announced he nearly doubled his share counts in Wal-Mart during the summer. Share count rose from 19.9 million shares to 37.84 million shares (90% increase). In addition to Wal-Mart, he also bought more Exxon. Both companies are listed in our watch list. - Art

Stock to Watch: Cardinal Health (CAH)

Cardinal Health (CAH) is one of the leading wholesale distributors of pharmaceuticals, medical/surgical supplies, and related products to a broad range of health care customers. The company completed a unit spin-off, CareFusion (CFN), on 9/1/09. Any investors with shares of CAH at the end of August received 0.5 shares of CFN. As a result, CAH price was adjusted down to $25.11 on 9/1/09 from $34.58 on the previous day. Two weeks later, Goldman Sachs upgraded CAH to a "buy" rating from "neutral" with a target price of $31. The stock closed at $27.29 on that day.
I pitched Cardinal Health to my readers several times prior to this writing. The first was a simple technical look at this stock on 6/11, 7/11, and 8/20. What I saw then was a stock with great fundamental developing a strong technical pattern called "triple bottom". Today I pitch you Cardinal Health once again with the different view. If you purchased this stock without selling them as I did, you would have done very well. As an added bonus, you would've gained some shares of CareFusion which rose 10.5% since it began trading. So let's dig into the number.
Cardinal Health came back on my radar on 9/18 watch list as because it appeared to be within 20% from the yearly low. A closer look at CAH shows a revealing valuation proposition. CAH is currently trading at 1.11x book value, 12x Forward P/E, 6x Cash, and 2.6% dividend yield. The undervaluation appeared to be because of the split but CFN is also trading at a discount value when you see it is trading at 0.88x book value. CAH is estimated to grow 8.4% (based on low estimate) and with yield of 2.6% that is a good 11% return. The great thing is the top line revenue is expected to stay relatively flat which mean they will be more efficient.
Using dividend as an insurance against price decline, investors will be rewarded with $0.70 per shares or 2.6% yearly. With low earning estimate of $1.89 for 2010, the payout ratio is 37%. Taking the previous year dividend increase rate, I project that CAH will raise payout to $0.74 for 2011. Low end estimate is projected at $2.05 which brings payout ratio down to 36%.
My model shows CAH should be at $40 range but this is based on previous year results including figures from CFN.  Surely I could be wrong and price fall, but as a value investor, I will not get many chances to buy a medical company at or near its book value. Given that all CAH competitors (ABC, MCK, and OMI) are trading at more than 2.3x book value, CAH is deeply discounted at 1.1. My estimate shows any 1.95x book to be low end of CAH and that would bring share price to $47. A 74% gain! That is just crazy. I will probably re-buy this stock in the days ahead.
Art

Disclosure: All figures are from Yahoo! Finance as of 9/29/09